Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BCD-057 and Humira in Healthy Subjects
NCT07181694Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by BIOCAD. Primary endpoints: Area under the plasma concentration-time curve from time zero to infinity at 1680 hours and Maximum observed plasma concentration at 1680 hours. Started Mar 2025; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07181694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181694.